Global Life Science Business Partnering (GLSBP) - March 2026

Highlights of Deals in March – 2026

 

Acquisitions:

1.    Infosys to Acquire Leading Healthcare Digital Transformation Company, Optimum Healthcare IT for US$568 Million (INR 5,260 crore).

2.    Mankind acquires Roche's epilepsy brand Rivotril India market rights.

3.    Strides Pharma acquires Sandoz's generic portfolio Africa market rights.

4.    CORONA Remedies announced the acquisition of Wokadine from Dr. Reddy’s Laboratories.

5.    BPL Medical Technologies acquires Yozma BMtech to expand preventive diagnostics portfolio Diagnostics.

6.    Jubilant Ingrevia Limited signed a Share Purchase Agreement to acquire 100% equity stake in Remidex Pharma.

7.    Otsuka Pharma to acquire Transcend Therapeutics in US$1.225 Billion deal.

8.    Medtronic to buy Scientia Vascular in US$550 Million deal.

9.    Esperion to buy Corstasis and its nasal spray for edema for US$75 Million upfront.

 

Licensing:

1.    Emcure Pharmaceuticals signs distribution pact with Roche for nephrology, transplant medicine.

2.    Shilpa Biologicals and SteinCares ink licensing pact to expand access to biosimilars across Latin America.

3.    Torrent inks deal to co-market Zydus semaglutide generic. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

4.    HRV Global Life Sciences and Shodhana Laboratories ink strategic CDMO pact to fast-track high-science & next-generation API development.

5.    Aurobindo Pharma biosimilars arm, CuraTeQ Biologics has out-licensed its two products European market commercial rights to Germany's STADA Arzneimittel AG.

6.    Aagami client Syngulon announced a licensing agreement with Elanco Animal Health, granting worldwide access to Syngulon's  proprietary bacteriocin-based microbial selection technologies.

7.    Earendil Labs taps WuXi XDC’s tech in US$885 Million ADC partnership.

8.    GSK licenses pill for liver disease itch to Alfasigma for US$300 Million upfront.

9.    Sanofi licenses Sino Biopharm's 'breakout star' transplant drug for US$135 Million upfront.

10. UCB boards T cell engager train in US$60 Million upfront deal with Antengene.

 

Investments/Fund Raising:

 

1.    Nova IVF picks up majority stake in Kerala's CRAFT Hospitals at US$40 Million valuation.

2.    Antiverse raises US$9.3 Million Series A and partners with Cystic Fibrosis Foundation.

 

 

Co-Development:

1.    Eveliqure and Serum Institute of India collaborate for development of anti-diarrhoeal vaccines.

2.    Secarna Pharma and Curie.Bio expand partnership.

3.    Ono Pharma inks new drug discovery deal with Congruence.

 

Aagami Updates:

1.     New Assignment: Out-Licensing a Novel and FDA validated Ionic Liquid delivery platform (Transdermal and Oral) for complex modalities and overcoming API challenges regarding solubility, absorption, and metabolic effects

2.     New Assignment: Out-Licensing and Distribution rights for Marketed Dental gel addressing Periodontitis, Gingivitis, & Caries.

3.     Contract Extension: Aagami has received contract extension from California client for partnering of their first in class eye drop to reverse cataract non-invasively.

4.     DCAT Week 2026: Our CEO participated in DCAT Week held in New York City from March 23–26, 2026. The event was highly productive, with over 25 strategic one-on-one meetings with decision makers, strengthening relationships and opening avenues for future collaborations.

5.     ChinaBio® 2026: Aagami will be participating in the ChinaBio® Partnering Forum in Shanghai on April 28–29, 2026. Partnering system is now open for meetings. He can also meet outside China Bio in Shanghai, on April, 27, 30, and May 01.

 

Select opportunities available:

For Partnering/Licensing/ Co-development:

  1. Seeking Licensing / Distribution Partners: Marketed Povidone-Iodine Nasal Spray (Nasodine®), patented, clinically proven to eliminate respiratory viruses and bacteria, offering safe and effective relief from cold, flu, and nasal congestion. Commercially launched in Singapore (2024) as an antiseptic liquid, with all government hospitals adoption and strong retail traction; Offering an attractive ready-to-launch Consumer wellness OTC opportunity in multiple markets (except Singapore, Brunei, Malaysia and the Philippines where already partnered).

2.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach).  By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.

3.     Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).

  1. Seeking Partnering/Co-development : Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.

5.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.

6.     Smart Polymeric best-in-class delivery system platform with long-acting injectables pipeline. Seeking partnering and investment.

7.     Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.

8.     Seeking Licensing / Co-development / Platform Partnering: FDA-validated Ionic Liquid (IL) enabled drug delivery platform addressing solubility, permeability, and bioavailability challenges. Enables non-invasive systemic delivery via transdermal and oral routes, including peptides and nucleic acids. Clinically validated with an FDA-approved IL-enabled product and demonstrated ~6× improvement in oral bioavailability (e.g., Semaglutide). Platform licensing, molecule-specific licensing, and joint R&D collaborations available. Email us about your challenging molecules at action@aagami.com

9.     Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028 market launch timeline.

 

For Acquisition:

1.    [URGENT] Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing.

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.

3.    A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.


For Investment:

1.     High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.

  1. Seeking US$3 Million: Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
  2. Seeking Investment: Revolutionizing oncology with patented smart drug delivery platform that enhances chemotherapy efficacy while minimizing toxic side effects. Backed by US$14 million in funding and a team with 7 prior drug launches, client is advancing a pipeline of 5 chemotherapies toward IND. Targeting US$180 billion+ oncology market.

Hope you found the content useful. We welcome your feedback and queries.